

Pacific Blue™ anti-mouse CD45 Antibody

Catalog# / Size	103125 / 25 µg 103126 / 100 µg
Clone	30-F11
Regulatory Status	RUO
Other Names	T200, Ly-5, LCA
Isotype	Rat IgG2b, κ
Description	CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Mouse thymus or spleen
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions.
Concentration	0.5 mg/ml
Storage & Handling	The CD45 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	<p>Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤ 0.25 µg per 10⁶ cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.</p> <p>* Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.</p> <p>Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.</p> <p>View full statement regarding label licenses</p>
Excitation Laser	Violet Laser (405 nm)
Application Notes	<p>Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.</p> <p>Additional reported applications (for relevant formats) include: immunoprecipitation³, complement-dependent cytotoxicity^{1,5}, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)^{4,6}, Western blotting⁷, and spatial biology (IBEX)^{10,11}. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).</p>
Application References	<ol style="list-style-type: none">1. Podd BS, <i>et al.</i> 2006. <i>J. Immunol.</i> 176:6532. (FC, CMCD) PubMed2. Haynes NM, <i>et al.</i> 2007. <i>J. Immunol.</i> 179:5099. (FC)
(PubMed link indicates	

BioLegend citation)

3. Ledbetter JA, *et al.* 1979. *Immunol. Rev.* 47:63. (IP)
4. Simon DI, *et al.* 2000. *J. Clin. Invest.* 105:293. (IHC)
5. Seaman WE. 1983. *J. Immunol.* 130:1713. (CMCD)
6. Cornet A, *et al.* 2001. *P. Natl. Acad. Sci. USA* 98:13306. (IHC)
7. Tsuboi S and Fukuda M. 1998. *J. Biol. Chem.* 273:30680. (WB) [PubMed](#)
8. Liu F, *et al.* 2012. *Blood.* 119:3295. [PubMed](#)
9. Pelletier AN, *et al.* 2012. *J. Immunol.* 188:5561. [PubMed](#)
10. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
11. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Perveen S, *et al.* 2012. *PLoS One.* 7:e51945. [PubMed](#)
2. Zabala M, *et al.* 2020. *Cell Stem Cell.* 27(2):284-299.e8. [PubMed](#)
3. Barkaway A, *et al.* 2021. *Immunity.* [PubMed](#)
4. Girbl T *et al.* 2018. *Immunity.* 49(6):1062-1076. [PubMed](#)
5. Komuczki J, *et al.* 2019. *Immunity.* 50:1289. [PubMed](#)
6. Turecamo SE, *et al.* 2018. *Matrix Biol.* 67:01:00. [PubMed](#)
7. Ma L, *et al.* 2009. *J Immunol.* 183:1044. [PubMed](#)
8. Aguilar EG, *et al.* 2021. *Blood Adv.* 5:4219. [PubMed](#)
9. Marchelletta RR, *et al.* 2021. *J Clin Invest.* 131:. [PubMed](#)
10. Quintero H, *et al.* 2022. *Cell Rep.* 40:111324. [PubMed](#)
11. Berube A, *et al.* 2022. *Viruses.* 14:. [PubMed](#)
12. Garcia-Fabiani MB, *et al.* 2020. *Methods Enzymol.* 632:369. [PubMed](#)
13. Furuta Y, *et al.* 2017. *PLoS One.* 12(2):e0172509. [PubMed](#)
14. Skowron K, *et al.* 2016. *Sci Rep.* 6:35854. [PubMed](#)
15. Oliveira-Lima OC, *et al.* 2015. *Immunobiology.* [PubMed](#)
16. Wietecha MS, *et al.* 2020. *Nat Commun.* 2.266666667. [PubMed](#)
17. Hastings AK, *et al.* 2019. *iScience.* 13:339. [PubMed](#)
18. Huang Z *et al.* 2017. *Cell metabolism.* 26(3):493-508. [PubMed](#)
19. Li H, *et al.* 2022. *Cell Rep Med.* 3:100554. [PubMed](#)
20. Reinitz F, *et al.* 2022. *Elife.* 11:. [PubMed](#)
21. Ferrere G, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
22. Fan L, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
23. Jacoby E, *et al.* 2021. *NPJ Regen Med.* 6:58. [PubMed](#)
24. Yamauchi T *et al.* 2018. *Cancer cell.* 33(3):386-400. [PubMed](#)
25. Fernandes RA, *et al.* 2020. *eLife.* 9:e58463.. [PubMed](#)
26. Rodriguez-García A, *et al.* 2021. *Nat Commun.* 12:877. [PubMed](#)
27. Song J, *et al.* 2021. *J Am Heart Assoc.* 10:e017329. [PubMed](#)
28. Fitzgerald B, *et al.* 2021. *Cell Rep Methods.* 1:. [PubMed](#)
29. Suárez-López L, *et al.* 2021. *iScience.* 24:103406. [PubMed](#)
30. Sauter M, *et al.* 2022. *iScience.* 25:103677. [PubMed](#)
31. Delacher M, *et al.* 2021. *Immunity.* 54(4):702-720.e17. [PubMed](#)
32. Stahnke S, *et al.* 2021. *Current Biology.* 31(10):2051-2064.e8. [PubMed](#)
33. Yuzhu Hou *et al.* 2018. *Immunity.* 49(3):490-503. [PubMed](#)
34. Peuhu E, *et al.* 2017. *PLoS One.* 12:e0186628. [PubMed](#)
35. Deslyper G, *et al.* 2021. *Parasitology.* 148:539. [PubMed](#)
36. Rao E, *et al.* 2021. *Sci Immunol.* 6:. [PubMed](#)
37. Leimkühler NB, *et al.* 2020. *Cell Stem Cell.* 28:637. [PubMed](#)
38. Chan A, *et al.* 2014. *Am J Pathol.* 184:1411. [PubMed](#)
39. Scheele C, *et al.* 2017. *Nature.* 542:313-317. [PubMed](#)
40. Okamoto T, *et al.* 2020. *Cancer Res.* 3580:80. [PubMed](#)
41. Hering L, *et al.* 2021. *Int J Mol Sci.* 22:. [PubMed](#)
42. Mitsune A, *et al.* 2021. *Respir Res.* 22:232. [PubMed](#)
43. Sperber HS, *et al.* 2020. *FASEB J.* 14615:34. [PubMed](#)
44. Dieterich LC, *et al.* 2019. *International Journal of Cancer.* 145(10):2804-2815. [PubMed](#)
45. Nie M, *et al.* 2016. *Cell Death Dis.* 7:e2261. [PubMed](#)
46. Shade K, *et al.* 2015. *J Exp Med.* 212:457. [PubMed](#)
47. Lee C, *et al.* 2014. *Cancer Res.* 74:341. [PubMed](#)
48. Shi C, *et al.* 2010. *J Immunol.* 184:6266. [PubMed](#)
49. Minatoguchi S, *et al.* 2022. *Sci Rep.* 12:5389. [PubMed](#)
50. Karaman S, *et al.* 2022. *J Exp Med.* 219:. [PubMed](#)
51. Guo HF, *et al.* 2021. *Commun Biol.* 4:482. [PubMed](#)
52. Cousin N, *et al.* 2021. *Cancer Res.* 81:4133. [PubMed](#)
53. Wan W, *et al.* 2013. *Cardiovasc Res.* 97:580. [PubMed](#)
54. Dubey LK, *et al.* 2019. *Cell Rep.* 27:2442. [PubMed](#)
55. Zhang F, *et al.* 2019. *Immunity.* 50:738. [PubMed](#)
56. An J, *et al.* 2022. *iScience.* 25:103570. [PubMed](#)
57. Jeong SJ, *et al.* 2021. *Autophagy.* 17:3740. [PubMed](#)
58. Menzel L, *et al.* 2022. *STAR Protoc.* 3:101267. [PubMed](#)
59. Chen D, *et al.* 2020. *Cancer Immunol Res.* 8:883. [PubMed](#)
60. Lovisa S, *et al.* 2020. *Sci Signal.* 13:00. [PubMed](#)
61. Len-Letelier RA, *et al.* 2020. *Frontiers in Immunology.* 11:583382. [PubMed](#)
62. Rosen D, *et al.* 2016. *J Infect Dis.* 213: 649 - 658. [PubMed](#)
63. Chun E, *et al.* 2020. *Immunity.* 51(5):871-884.e6.. [PubMed](#)
64. Lv Z, *et al.* 2020. *Oncoimmunology.* 9:1747688. [PubMed](#)
65. Deng Z, *et al.* 2017. *Oncogene.* 36:639. [PubMed](#)
66. Hartwig T *et al.* 2018. *Cell reports.* 25(13):3564-3572. [PubMed](#)
67. Bignami F, *et al.* 2017. *Acta Ophthalmol.* 95:e641. [PubMed](#)
68. Mrdjen D *et al.* 2018. *Immunity.* 48(2):380-395. [PubMed](#)

69. Mifflin L, *et al.* 2021. Proc Natl Acad Sci U S A. 118:. [PubMed](#)
70. Vanuytsel K, *et al.* 2022. Nat Commun. 13:1103. [PubMed](#)
71. Cheah M, *et al.* 2015. Proc Natl Acad Sci U S A. 112:4725. [PubMed](#)
72. Cheng Q, *et al.* 2020. Nat Nanotechnol. 0.842361111. [PubMed](#)
73. Souza COS, *et al.* 2021. iScience. 24(6):102548. [PubMed](#)
74. Thiriot A *et al.* 2017. BMC biology. 15(1):45 . [PubMed](#)
75. Taniguchi H, *et al.* 2022. Cell Rep. 39:110814. [PubMed](#)
76. Tacconi C, *et al.* 2021. Cell Reports. 35(2):108993. [PubMed](#)
77. Mender I, *et al.* 2020. Cancer Cell. 38(3):400-411.e6. [PubMed](#)
78. Barsoumian HB, *et al.* 2020. J Immunother Cancer. 8:00. [PubMed](#)
79. McCoy S 2015. Am J Physiol Lung Cell Mol Physiol. 309: L463-L474. [PubMed](#)
80. Frasca D, *et al.* 2020. Front Immunol. 11:328. [PubMed](#)
81. Mishra BB, *et al.* 2017. Nat Microbiol. 2:17072. [PubMed](#)
82. Cai S *et al.* 2017. Cell stem cell. 20(2):247-260 . [PubMed](#)
83. Lee DH, *et al.* 2019. PLoS One. 14:e0215727. [PubMed](#)
84. Niknam S, *et al.* 2018. Clin Cancer Res. 24:5735. [PubMed](#)
85. Hu Y, *et al.* 2022. J Nanobiotechnology. 20:417. [PubMed](#)
86. Chang J, *et al.* 2016. J Am Soc Nephrol. 10.1681/ASN.2015121356. [PubMed](#)
87. Hiebert P *et al.* 2018. Developmental cell. 46(2):145-161 . [PubMed](#)
88. Diéguez-Hurtado R, *et al.* 2019. Nat Commun. 10:2817. [PubMed](#)
89. Lee S *et al.* 2017. Cell host & microbe. 22(4):449-459 . [PubMed](#)
90. Liang J, *et al.* 2020. Sci Adv. 6:eabc3646. [PubMed](#)
91. Gusarova GA, *et al.* 2021. JCI Insight. 6: . [PubMed](#)
92. Tan X, *et al.* 2021. Sci Adv. 7: . [PubMed](#)
93. Li C, *et al.* 2021. Cell Metabolism. 33(8):1610-1623.e5. [PubMed](#)
94. Sungur C, *et al.* 2013. Proc Natl Acad Sci U S A. 110:7401. [PubMed](#)
95. Qiao J, *et al.* 2019. Cancer Cell. 35:901. [PubMed](#)
96. Yamada KJ, *et al.* 2020. PLoS Pathog. 16:e1008354. [PubMed](#)
97. Williams JW, *et al.* 2017. Circ Res. 121:662. [PubMed](#)
98. Tomay F, *et al.* 2019. J Transl Med. 17:237. [PubMed](#)
99. Sydney Lavoie *et al.* 2019. eLife. 8 pii: e39982. [PubMed](#)
100. Mantilla-Rojas C, *et al.* 2022. Cancers (Basel). 14:. [PubMed](#)
101. Prizant H, *et al.* 2021. Cell Reports. 36(6):109523. [PubMed](#)
102. Su W *et al.* 2019. Cancer Cell. 36(2):139-155 . [PubMed](#)
103. Fujimoto N, *et al.* 2020. PLoS Biol. 18:e3000704. [PubMed](#)
104. Lebel MÈ, *et al.* 2020. Nat Commun. 3.051388889. [PubMed](#)
105. Quenum Zangbede FO, *et al.* 2018. J Neurosci. 38:6737. [PubMed](#)
106. Nishida C, *et al.* 2012. Blood. 119:5405. [PubMed](#)
107. Spix B, *et al.* 2022. Nat Commun. 13:318. [PubMed](#)
108. Zhang Y, *et al.* 2022. Vaccines (Basel). 10:. [PubMed](#)
109. Li Q, *et al.* 2022. Front Cardiovasc Med. 9:872102. [PubMed](#)
110. Han Y, *et al.* 2022. Int J Biol Sci. 18:5653. [PubMed](#)
111. Huang S, *et al.* 2020. Cell. 184(2):441-459.e25. [PubMed](#)
112. Heim CE, *et al.* 2020. Nature Microbiology. 5(10):1271-1284. [PubMed](#)
113. Gong N, *et al.* 2020. Nat Nanotechnol. 1.35625. [PubMed](#)
114. Vacca F, *et al.* 2020. eLife. 9:e54017.. [PubMed](#)
115. Chia JSJ, *et al.* 2018. Nutrients. 1.313194444. [PubMed](#)
116. Li Y *et al.* 2018. Cell Stem Cell. 23(2):181-192 . [PubMed](#)
117. Xueyang Yu *et al.* 2017. Immunity. 47(5):903-912 . [PubMed](#)
118. Engblom C, *et al.* 2017. Science. 358:6367. [PubMed](#)
119. Hou Y, *et al.* 2021. Sci Transl Med. 13:. [PubMed](#)
120. Song J, *et al.* 2021. Am J Physiol Heart Circ Physiol. 320:H323. [PubMed](#)
121. McAndrews KM, *et al.* 2021. J Biol Chem. 296:100523. [PubMed](#)
122. Choudhary S, *et al.* 2012. J Virol. 86:114. [PubMed](#)
123. Younes Al, *et al.* 2021. Transl Oncol. 14:100983. [PubMed](#)
124. Kato K, *et al.* 2018. Nat Commun. 48:120. [PubMed](#)
125. Li C, *et al.* 2018. Cell. 174:285. [PubMed](#)
126. iwata TN, *et al.* 2018. Mol Cancer Ther. 17:1494. [PubMed](#)
127. Yousef H, *et al.* 2019. Nat Med. 25:988. [PubMed](#)
128. Li F, *et al.* 2022. Nat Commun. 13:4334. [PubMed](#)
129. Zhang Y, *et al.* 2021. Commun Biol. 344:4. [PubMed](#)
130. Pfirsckhe C, *et al.* 2020. Cell Rep. 32:108164. [PubMed](#)
131. McKenzie MD, *et al.* 2019. Cell Stem Cell. 25:258. [PubMed](#)
132. Aoto M, *et al.* 2019. FEBS Open Bio. 9:291. [PubMed](#)
133. Ualiyeva S, *et al.* 2021. Bio Protoc. 11:e4163. [PubMed](#)
134. Ko FC, *et al.* 2021. J Bone Miner Res. 36:1510. [PubMed](#)
135. Li Y, *et al.* 2022. STAR Protoc. 3:101364. [PubMed](#)
136. Leary N, *et al.* 2022. J Extracell Vesicles. 11:e12197. [PubMed](#)
137. Hering L, *et al.* 2020. Front Immunol. 1.747222222. [PubMed](#)
138. Yao Z, *et al.* 2020. Cancer Res. 80:1171. [PubMed](#)
139. Stefan KL, *et al.* 2020. Cell. 1312:183. [PubMed](#)
140. Gomes AM, *et al.* 2018. Cell Rep. 25:2821. [PubMed](#)
141. Yoshida H, *et al.* 2019. Cell. 176:897. [PubMed](#)
142. Rui J, *et al.* 2021. Nat Commun. 12:5074. [PubMed](#)
143. Wang R, *et al.* 2022. J Immunother Cancer. 10:. [PubMed](#)
144. Tang S, *et al.* 2022. Virol J. 19:32. [PubMed](#)
145. Chen Y, *et al.* 2021. Cancer Cell. 39(4):548-565.e6. [PubMed](#)
146. Carson W, *et al.* 2011. PLoS One. 6:e20385. [PubMed](#)
147. Ramanan D, *et al.* 2020. Cell. 181(6):1276-1290. [PubMed](#)
148. Forese MG *et al.* 2019. Glia. 68(1):95-110 . [PubMed](#)

149. Zilionis R *et al.* 2019. *Immunity*. 50(5):1317-1334 . [PubMed](#)
150. Tucey TM *et al.* 2018. *Cell metabolism*. 27(5):988-1006 . [PubMed](#)
151. Weidner T, *et al.* 2021. *Nat Protoc*. 16:3210. [PubMed](#)
152. Yamaguchi T, *et al.* 2020. *Eur J Immunol*. 50:110. [PubMed](#)
153. Barsoumian HB, *et al.* 2022. *Cancers (Basel)*. 14:. [PubMed](#)
154. Fite BZ, *et al.* 2021. *Sci Rep*. 11:927. [PubMed](#)
155. Sasai M, *et al.* 2021. *J Exp Med*. 218:. [PubMed](#)
156. Kurashima Y, *et al.* 2021. *Nat Commun*. 12:1067. [PubMed](#)
157. Manriquez V, *et al.* 2021. *Nat Commun*. 12:4547. [PubMed](#)
158. Chavkin NW, *et al.* 2021. *J Am Heart Assoc*. 10:e019904. [PubMed](#)
159. Pattabiraman D, *et al.* 2016. *Science*. 351: aad3680. [PubMed](#)
160. Borrelli MR, *et al.* 2020. *Stem Cells Transl Med*. 1.347916667. [PubMed](#)
161. Hemanthakumar KA, *et al.* 2021. *eLife*. 10:00. [PubMed](#)
162. Li M, *et al.* 2020. *Nat Commun*. 4051:11. [PubMed](#)
163. Eilken H, *et al.* 2017. *Nat Commun*. . 10.1038/s41467-017-01738-3. [PubMed](#)
164. Thurlow LR, *et al.* 2018. *Cell Host Microbe*. 24:261. [PubMed](#)
165. Avey D *et al.* 2018. *Cell reports*. 24(13):3619-3629 . [PubMed](#)
166. Li A, *et al.* 2018. *Cancer Lett*. 431:54. [PubMed](#)
167. Mahmoudi S, *et al.* 2019. *Nature*. 574:553. [PubMed](#)
168. Caetano MS, *et al.* 2019. *Clin Cancer Res*. 25:7576. [PubMed](#)
169. Hu Y, *et al.* 2021. *J Nanobiotechnology*. 19:416. [PubMed](#)
170. Shue YT, *et al.* 2022. *Nat Commun*. 13:2690. [PubMed](#)
171. Kastenschmidt JM, *et al.* 2021. *Cell Rep*. 35:108997. [PubMed](#)
172. Cortez MA, *et al.* 2020. *Nat Commun*. 3.819444444. [PubMed](#)
173. Hayashi K, *et al.* 2020. *Nat Commun*. 4.832638889. [PubMed](#)
174. Zysset D, *et al.* 2016. *Nat Commun*. 7:13151. [PubMed](#)
175. Denk F, *et al.* 2016. *Cell Rep*. 15: 1771-1781. [PubMed](#)
176. Jiang Q, *et al.* 2008. *Blood*. 112:2858. [PubMed](#)
177. Maas SLN, *et al.* 2020. *J Neuroinflammation*. 17:120. [PubMed](#)
178. Barry DM, *et al.* 2019. *Nat Commun*. 4.378472222. [PubMed](#)
179. Jorge Domínguez-Andrés *et al.* 2017. *Immunity*. 46(6):1059-1072 . [PubMed](#)
180. Omenetti S, *et al.* 2019. *Immunity*. 51:77. [PubMed](#)
181. Di Liberto G *et al.* 2018. *Cell*. 175(2):458-471 . [PubMed](#)
182. Shao S, *et al.* 2020. *Proc Natl Acad Sci U S A*. 117:8845. [PubMed](#)
183. Tseng SH, *et al.* 2021. *J Biomed Sci*. 28:63. [PubMed](#)

RRID AB_493536 (BioLegend Cat. No. 103125)
 AB_493535 (BioLegend Cat. No. 103126)

Antigen Details

Structure	Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution	All hematopoietic cells except mature erythrocytes and platelets
Function	Phosphatase, T and B cell activation
Ligand/Receptor	Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type	B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area	Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family	CD Molecules
Antigen References	<ol style="list-style-type: none"> 1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press. 2. Trowbridge IS, <i>et al.</i> 1993. <i>Annu. Rev. Immunol</i>. 12:85. 3. Kishihara K, <i>et al.</i> 1993. <i>Cell</i> 74:143. 4. Pulido R, <i>et al.</i> 1988. <i>J. Immunol</i>. 140:3851.
Gene ID	19264


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD45, Biotin anti-mouse CD45, FITC anti-mouse CD45, PE anti-mouse CD45, PE/Cyanine5 anti-mouse CD45, Purified anti-mouse CD45, PE/Cyanine7 anti-mouse CD45, APC/Cyanine7 anti-mouse CD45, Alexa Fluor® 488 anti-mouse CD45, Alexa Fluor® 647 anti-mouse CD45, Pacific Blue™ anti-mouse CD45, Alexa Fluor® 700 anti-mouse CD45, PerCP/Cyanine5.5 anti-mouse CD45, PerCP anti-mouse CD45, Alexa Fluor® 594 anti-mouse CD45, Brilliant Violet 421™ anti-mouse CD45, Brilliant Violet 570™ anti-mouse CD45, Brilliant Violet 510™ anti-mouse CD45, Brilliant Violet 605™ anti-mouse CD45, Purified anti-mouse CD45 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD45, Brilliant Violet 711™ anti-mouse CD45, Brilliant Violet 785™ anti-mouse CD45, Brilliant Violet 650™ anti-mouse CD45, APC/Fire™ 750 anti-mouse CD45, Brilliant Violet 750™ anti-mouse CD45, TotalSeq™-A0096 anti-mouse CD45, TotalSeq™-B0096 anti-mouse CD45, Ultra-LEAF™ Purified anti-mouse CD45, Spark Blue™ 550 anti-mouse CD45, Spark NIR™ 685 anti-mouse CD45, TotalSeq™-C0096 anti-mouse CD45, Spark YG™ 570 anti-mouse CD45, PE/Fire™ 640 anti-mouse CD45, APC/Fire™ 810 anti-mouse CD45, PE/Fire™ 700 anti-mouse CD45, Spark Violet™ 538 anti-mouse CD45, Spark YG™ 593 anti-mouse CD45, Spark Blue™ 574 anti-mouse CD45 Antibody

Product Data



C57BL/6 mouse splenocytes stained with Pacific Blue™ 30-F11

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587